fbpx

Focus on Talcum Powder and Ovarian Cancer

Last Updated November 11, 2020

As far back as the 1960s, medical researchers first suggested the possibility that talcum powder sprinkled on female genitalia could be linked with ovarian cancer. Their belief stemmed from the knowledge that talc naturally contains asbestos, a fibrous mineral with a well-established connection to increased cancer risk. Years later, in 1982, scientists conducted the first case-control study to link talcum powder and ovarian cancer. Since then, more and more studies have followed confirming an association with increased risk.

Talc is a naturally occurring mineral that can be crushed, dried, and milled to form a fine, soft, white powder that has a propensity to absorb moisture and reduce friction. Usually, talc is mined in close proximity to deposits of asbestos. Despite the potential for asbestos contamination, talc has been a very popular ingredient in personal care and cosmetic products in the United States for decades. In 1976, in an effort to beat federal and state regulators to the punch, an industry trade association, the Cosmetics, Toiletry and Fragrances Association (CTFA) proposed that the industry be allowed to self-regulate with voluntary standards requiring that all member companies market products which are “free of detectable amounts of asbestos”. “Detectable” is an important distinction as many research experts will contend that even small or virtually undetectable amounts of asbestos can potentially increase cancer risk substantially.

Products such as Johnson & Johnson Baby Powder were aggressively promoted to American consumers for over a century. Originally pitched as a drying and diaper friction solution to mothers for their babies, use of talcum based powder began to wane as parents, concerned with risks from inhalation, switched to other solutions such as corn starch. Accordingly, manufacturers of talcum powders began to switch their marketing focus toward women in general, promoting talcum powder as a solution for genital odors, perspiration, and moisture. Johnson & Johnson even specifically targeted “curvy” and overweight African-American women in its advertising as the use of baby powder underwent a demographic shift. These campaigns were wildly successful and by the mid-2000s, adults accounted for 91% of Johnson’s Baby Powder use.

Despite the studies and evolving knowledge concerning the association between talc-based powders and ovarian cancer, Johnson & Johnson and other manufacturers continue to insist that their talc-based powders are asbestos-free and do not cause cancer. And to be sure, there exists no definitive evidence that talcum powder causes ovarian cancer.  Nevertheless, in May 2020, Johnson & Johnson announced that it was discontinuing sales of talc-based powder products in North America. The company will allow existing bottles of baby powder to be sold by retailers until supplies run out.

Talcum Powder

Evolving Understanding of Ovarian Cancer Risk

The first epidemiologic study involving talcum powder use on female genitalia was performed in 1982 by Dr. Daniel Cramer and his team of researchers. Dr. Cramer’s study found a significantly increased risk of ovarian cancer in women who reported that they regularly used talcum powder in their genital area. According to Dr. Cramer, officials from Johnson & Johnson came to discuss his study.  At that time, Dr. Cramer recommended to Johnson & Johnson that they place a warning on its talcum powder about the risk of ovarian cancer. Since the Cramer study, there have been approximately 22 additional epidemiologic studies that have reported an elevated risk for ovarian cancer associated with talcum use on female genitalia. Among these studies and findings:

  • In 1993, the U.S. National Toxicology Program (USNTP) published a study on the toxicity of non-asbestiform talc and, according to their statement, found clear evidence of “carcinogenic activity”.
  • The International Association for the Research of Cancer (IARC), a unit of the World Health Organization (WHO) published a paper in 2006 wherein it classified perineal use (i.e. in the area of the female genitalia) of talcum based powder as a “Group 2B” human carcinogen. IARC is widely accepted as the international authority on cancer issues.
  • The IARC found that between 16-52% of women in the world were using talcum powder to dust their genitals and found that among them there was an increased risk of ovarian cancer ranging from 30-60%.
  • The Canadian government classified talc as a “D2A – Very Toxic” cancer-causing substance under its Hazardous Products Act. Notably, asbestos is similarly labeled as D2A.
  • The journal “Epidemiology” published the article “The Association Between Talc Use and Ovarian Cancer” in May 2016 which examined the association in 2,041 cases of ovarian cancer and genital talcum powder use. The article concluded with the observation that the use of talcum on the genitals is associated with elevated ovarian cancer risk vs. no increased risk among women who did not use talcum powder on the genitals.
  • A study headed up by Joellen M. Schildkraut, Ph.D., MPH, was published in the October 2016 journal “Cancer and Epidemiology, Biomarkers, Prevention”, which indicated that African American women had a substantially higher risk for ovarian cancer if they used talcum to powder their genitalia.

Regulators and the Industry

Manufacturers of talcum powder products are not required to provide safety information in the United States. The U.S. Food and Drug Administration (FDA) has opined in the past that it does not believe it has the authority to require any sort of warning on talcum powder. However, in 2016, the FDA’s Office of Women’s Health (OWH) did announce its funding of additional research into the potential for a relationship between talcum powder and ovarian cancer, acknowledging that its effects on female genitalia have not been adequately investigated. The OWH research is aimed at filling in “data gaps” in the association of talcum powder and the onset of cancerous conditions.

Johnson & Johnson and other talcum-based product manufacturers uniformly continue to insist that their products are both asbestos-free and do not cause cancer. In May 2020, Johnson & Johnson announced that it would discontinue sales of baby powder in North America.


Sources Cited (13):

1) “Asbestos and Cancer Risk” https://www.cancer.org/cancer/cancer-causes/asbestos.html

2) “Estate of Maureen Broderick Milliken, Deceased v. Johnson & Johnson, et al.” Case 2:16-cv-02866-MAK, U.S. District Court, Eastern District of Pennsylvania.

3) “The Association Between Talc Use and Ovarian Cancer” https://journals.lww.com

4) “Association between Body Powder Use and Ovarian Cancer: the African American Cancer Epidemiology Study (AACES)” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050086/

5) “Joellen M. Schildkraut, PhD, MPH” https://winshipcancer.emory.edu/bios/faculty/schildkraut-joellen.html

6) “Non-clinical mechanistic studies in addressing ovarian cancer risk from talc use in cosmetics” https://www.fda.gov/science-research/womens-health-research/owh-funded-research-cancer

7) “Cancer Prevention Coalition Letter – November 17, 1994” https://www.reuters.com/investigates/special-report/assets/usa-health-fda-talc/epstein-petition.pdf

8) “JAMA Study Finds No Significant Link Between Talc Powder, Ovarian Cancer” https://www.ajmc.com/view/jama-study-finds-no-link-between-talc-powder-ovarian-cancer

9) “IARC Monographs on the Evaluation of Carcinogenic Risks to Humans” https://monographs.iarc.fr/wp-content/uploads/2018/06/mono93.pdf

10) “Health Canada: Learn about talc and if it’s safe.” https://www.canada.ca/en/health-canada/services/chemicals-product-safety/talc.html

11) “Safety Data Sheet” https://www.gusmerenterprises.com/wp-content/uploads/2015/12/Talc-SDS.pdf

12) “Johnson & Johnson to End Talc-Based Baby Powder Sales in North America” https://www.nytimes.com/2020/05/19/business/johnson-baby-powder-sales-stopped.html

13) “Johnson & Johnson Ends North American Sales of Talc-Based Baby Powder” https://www.cancerhealth.com/article/johnson-johnson-ends-north-american-sales-talcbased-baby-powder

Tracy Everhart is the Editor for Drug Law Journal. A highly-trained and certified medical professional, Tracy is also an accomplished medical writer. After spending years on the front lines of the medical profession, Tracy now devotes her expertise and skills to researching and reporting on new drugs and devices that enter the market, as well as their side-effects and the real-life stories involved. Prior to joining Drug Law Journal, Tracy wrote for benchmark online healthcare resources focused on families and, in particular, women’s health issues. Tracy holds post-graduate degrees from both the American College of Healthcare Sciences and the Yale School of Nursing. She is also a graduate of both Hampshire College, where she studied microbiology and the University of South Carolina school of nursing.

Drug Law Journal Legal Sponsorship

Drug Law Journal's publishing and research are sponsored by the DDP Injury Law Group in Washington, D.C. Their legal team is focused on protecting the rights of injury victims.
Furthermore, they understand and appreciate the importance of a trusted attorney-client relationship.
The DDP Injury Law Group uses their years of experience with litigation to ensure their clients can fight for the compensation they deserve.

Always seek the advice of a medical professional when making personal health choices.

The Offices of DrugLawJournal.com are located at:

1800 North Orange Avenue, Suite C
Orlando, Florida 32804

DrugLawJournal.com is sponsored by the DDP Injury Law Group, and therefore may be considered attorney advertising. The information contained on DrugLawJournal.com is provided for informational purposes only, and should not be construed as legal or medical advice on any subject matter. No viewers of this site should discontinue taking a prescribed medication on the basis of any information on this site and should always first consult with a doctor concerning any medication. Viewers should understand that if they refrain from taking prescribed medication without appropriate medical advice they can suffer injury or death.

No viewers of content from this site, clients or otherwise, should act or refrain from acting on the basis of any content included in the site without seeking the appropriate legal or other professional advice on the particular facts and circumstances at issue from an attorney licensed in the viewer’s state. Viewing information from DrugLawJournal.com does not create an attorney-client relationship between you and DDP Injury Law Group or DrugLawJournal.com nor is it intended to do so.The content of DrugLawJournal.com may not reflect current legal developments, verdicts or settlements. Prior results do not predict a similar outcome. For more information, please visit our web site’s disclaimer.

©2024 DrugLawJournal.com | Privacy Policy | Terms & Conditions

Stay Informed

Sign up to receive peroidic updates from our expert team of researchers, highlighting defective drugs, devices, and legal issues related to your health.

Email Catcher
Free Drug and Medical Device Case Review

Free Drug and Medical Device Case Review

Share your story with us and we will reach out to you about your case.

First
Last
Described what happened to you, we will review and reach out to you about your situation.

It is important for those who have suffered injury from dangerous drugs and medical devices to know that they have may have options.

Consumers have the ability to seek legal remedies for their injuries resulting from the negligence of drug and device manufacturers. The first step toward justice and recovery is sharing your story with effective legal counsel. An attorney will help you to better understand the issues and discuss the possibility of compensation for your suffering.

Once you complete the information request above, Drug Law Journal will send the information to a specialist at our legal sponsor’s firm, the DDP Injury Law Group, in Washington, D.C. That specialist will follow-up with you directly to gather further specific information about your case and make an evaluation. If the firm is able to move forward on your case, they will also discuss next steps. Remember – the entire consult and evaluation is free to you. You only need to take the first step to fill out the contact form or call: (800) 597-1870 for immediate assistance.